Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    PROGESTERONE RESISTANCE
Show Display Options
Rank Status Study
1 Active, not recruiting Therapeutic Estradiol and Exemestane in Treating Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: therapeutic estradiol;   Drug: exemestane;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay
2 Recruiting Hormone Blockade in Combination With Targeted Agents
Conditions: Solid Tumors;   Advanced Cancer
Interventions: Drug: Anastrozole;   Drug: Bevacizumab;   Drug: Everolimus;   Drug: Sorafenib;   Drug: Erlotinib
3 Active, not recruiting Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Conditions: Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Intervention: Drug: Exemestane

Indicates status has not been verified in more than two years